Erasca (ERAS) Long-Term Investments (2021 - 2026)
Erasca's (ERAS) quarterly Long-Term Investments came in at $164.7 million in Q1 2026, up 54.67% YoY from $106.5 million in Q1 2025, and up 150.63% on a QoQ basis from $65.7 million in Q4 2025.
Erasca (ERAS) Long-Term Investments (2021 - 2026) Analysis & Trends
Erasca (ERAS) has 6 years of Long-Term Investments data on file, last reported at $164.7 million in Q1 2026.
- Quarterly Long-Term Investments rose 54.67% year-over-year to $164.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.7 million (up 54.67% YoY) and the FY2025 annual result came in at $65.7 million, down 53.77% from the prior year.
- Long-Term Investments advanced to $164.7 million in Q1 2026, from $65.7 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $164.7 million in Q1 2026 to a low of $9.6 million in Q3 2022.
- A 5-year average of $71.3 million and a median of $58.8 million in 2024 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2024 — Long-Term Investments soared 1374.42% — and 2025, when it slumped 53.77%.
- Tracing ERAS's Long-Term Investments over 5 years: stood at $9.6 million in 2022, then advanced by 0.76% to $9.6 million in 2023, then soared by 1374.42% to $142.2 million in 2024, then tumbled by 53.77% to $65.7 million in 2025, then soared by 150.63% to $164.7 million in 2026.
- The last three Long-Term Investments figures came in at $164.7 million (Q1 2026), $65.7 million (Q4 2025), and $74.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 115.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.53 Mn |
| Mar 31, 2026 | 164.72 Mn |
| Dec 31, 2025 | 65.72 Mn |
| Sep 30, 2025 | 73.98 Mn |
| Jun 30, 2025 | 86.09 Mn |
| Mar 31, 2025 | 106.50 Mn |
| Dec 31, 2024 | 142.16 Mn |
| Sep 30, 2024 | 144.39 Mn |
| Jun 30, 2024 | 51.84 Mn |
| Dec 31, 2023 | 9.64 Mn |
| Sep 30, 2023 | 46.89 Mn |
| Jun 30, 2023 | 48.08 Mn |
| Sep 30, 2022 | 9.57 Mn |
| Jun 30, 2022 | 19.31 Mn |
| Mar 31, 2022 | 29.22 Mn |
| Dec 31, 2021 | 44.77 Mn |
| Jun 30, 2021 | 5.00 Mn |